Tag Archives: regeneron pharmaceuticals

A few stocks, including some of the ones below, are being classified as COVID-19 stocks because of their potential to rise even as the pandemic worsens.Apart from the obvious health effects, the current coronavirus pandemic has already depleted financial markets all over the world. As the outbreak continues to spread and the world records a lot more confirmed cases, these economic effects are also going to continue. Many companies are already recording heavy losses and many of the world’s...

Avigan, also known as Favipiravir, is a Japanese flu drug developed by the healthcare arm of Fujifilm. 340 patients taking the drug found it reduces recovery time and improves their lung condition. Enthralled by COVID-19, the world is waiting for a hero who will find the coronavirus vaccine. And one of the most widely-discussed variants to treat coronavirus today is Favipiravir (or Avigan). Worldwide famous biotech companies such as Gilead Sciences Inc (NASDAQ: GILD), Inovio Pharmaceuticals...

Inovio (INO) stock has now erased some of its YTD gains after Citron Research suggested the company was grandstanding. Citron’s analysts now put INO at $2.Several factors affect the volatility of financial markets all over the world. In recent times, it’s been the coronavirus outbreak. The uncertainty and fear have caused a general plunge in the markets. However, some stocks – specifically biotech companies – rode on the epidemic for a time, and increased in value. Inovio Pharmaceuticals Inc...

Dow Jones has lost over 1,880 points due to a row of factors including Saudi’s oil price slash as well as the coronavirus that is quickly spreading. More bleeding is expected.All over the world, markets have been feeling terrible effects of the coronavirus COVID-19 outbreak. In recent times, the epidemic has caused stocks to plunge considerably, with a lot of companies seriously bleeding. Projections for the coronavirus have been quite pessimistic with forecasts that things will get worse....

As major biotech companies try to create a proper coronavirus vaccine, the following stocks just might be strong enough to hedge against the current financial plunge.The coronavirus epidemic isn’t letting down as many people hope it would. Instead, the number of confirmed cases as well as the mortality rate, are on a steady rise. The number of countries affected by the virus is also increasing steadily with many more countries confirming new cases of infection. The situation is worrisome to...

French multinational company Sanofi SA stated on Monday that it will buy biotechnology company Synthorx Inc. for a combined equity value of approximately $2.5 billion. In other words, it will be $65 per share.The acquisition is expected to close in the first quarter in 2020 and the company believes it will strengthen Sanofi’s existing immuno-oncology portfolio.Paul Hudson, who is the CEO of Sanofi, said:“This acquisition fits perfectly with our strategy to build a portfolio of high-quality...